Novartis
- All
- News
- Videos
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis India Sheds Over 6% Even After Net Profit Rises 43% In March Quarter
Novartis India Share Price Today: On Friday, Novartis India opened on the BSE at Rs 881, swinging to an intra day high of Rs 883.35 and an intra day low of Rs 797.35, so far
-
Stocks To Watch: PowerGrid Corporation, Novartis India, Natco Pharma
PowerGrid Corporation reported a 6 per cent rise in consolidated net profit to Rs 3,526.23 crore in the quarter ended March 2021 from Rs 3,313.47 crore in the same quarter last fiscal
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Swiss Drugmaker Novartis To Help Make Pfizer-Biontech Coronavirus Vaccine
Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
-
Swiss Firm Novartis Stops Hydroxychloroquine Trial For COVID-19 Treatment
Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Google Parent Alphabet's Verily Unit Halts Glucose-Detecting Contact Lens Project
Verily, which was previously part of the tech firm's Google X research and development unit, had partnered with Novartis' eye-care division, Alcon, to develop the lens.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Novartis India Sheds Over 6% Even After Net Profit Rises 43% In March Quarter
Novartis India Share Price Today: On Friday, Novartis India opened on the BSE at Rs 881, swinging to an intra day high of Rs 883.35 and an intra day low of Rs 797.35, so far
-
Stocks To Watch: PowerGrid Corporation, Novartis India, Natco Pharma
PowerGrid Corporation reported a 6 per cent rise in consolidated net profit to Rs 3,526.23 crore in the quarter ended March 2021 from Rs 3,313.47 crore in the same quarter last fiscal
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Swiss Drugmaker Novartis To Help Make Pfizer-Biontech Coronavirus Vaccine
Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
-
Swiss Firm Novartis Stops Hydroxychloroquine Trial For COVID-19 Treatment
Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Google Parent Alphabet's Verily Unit Halts Glucose-Detecting Contact Lens Project
Verily, which was previously part of the tech firm's Google X research and development unit, had partnered with Novartis' eye-care division, Alcon, to develop the lens.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
GSK Set To Buy Novartis Stake In Joint Venture For $13 Billion, Might Lose Horlicks Brand
Completion of the buyout by GSK of Novartis 36.5% stake in the joint venture is currently expected to occur during the summer of 2018.
-
GSK Buys Novartis Stake In Consumer Healthcare Venture For $13 billion
The deal is set to complete in the second quarter subject to the necessary approvals.
